![Page 1: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/1.jpg)
Top Dermatology Challenges in Primary Care
Update in Internal MedicineOctober 10-11, 2019
Pittsburgh, PA
![Page 2: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/2.jpg)
Disclosures
• I am a consultant for DermTech, Eli Lilly, Janssen, Ortho, Pfizer• I am an investigator for DermTech, Eli Lilly, Janssen, Ortho, Amgen,
Abbvie, Novartis, Leo Pharma, Galderma, Boehrenger Ingelheim, Celgene
![Page 3: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/3.jpg)
Topics to cover
• Skin cancer screening in primary care• Dermatologic effects of medications you may prescribe• Medical side effects of dermatologic medications you may encounter• Medical comorbidities of common dermatologic diseases• Easy to miss diagnoses• Common conditions and how to treat
![Page 4: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/4.jpg)
Skin cancer screening and prevention in the primary care
setting
![Page 5: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/5.jpg)
Source: SEER.cancer.gov
INVASIVE ONLY(40% of melanomas are in situ)
5th most common cancer in men
7th most common cancer in women
• Men > Women• Risk factors: UV exposure, + family
history, fair skin / light hair
![Page 6: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/6.jpg)
Melanoma: clinical features
regression
Ugly ducklingEvolving
![Page 7: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/7.jpg)
USPSTF recommendations for skin cancer screening
•“The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in adults “
•Screening = full body visual examination of the skin
US Preventive Services Task Force. JAMA. 2016 Jul 26;316(4):429-35.
![Page 8: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/8.jpg)
Behavioral Counseling•Updated USPSTF recommendations for counseling to prevent skin cancer
JAMA. 2018 Mar 20;319(11):1134-1142.
![Page 9: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/9.jpg)
Melanoma screening at UPMC
§ Collaboration with primary care– QUALITY INITIATIVE§ Non-randomized, voluntary§ Use of existing health care data infrastructure and workflow§ PCPs trained to identify skin cancer using validated online training module § Patients age ≥35 offered screening annually by PCPs during routine visits§ Health maintenance module within EHR modified to identify eligible patients
and track screening activity§ Outcomes collected from EHR, cancer registry, health plan
JAMA Oncol. 2017 Aug 1;3(8):1112-1115
![Page 10: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/10.jpg)
INFORMED training (visualdx.com)
![Page 11: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/11.jpg)
All screen eligible
Screened Not screened
p-value
Overall patient # (n, % total eligible)
333,735 53,196
(15.9%)
280,539
(84.1%)
% Male 43.1% 43.2% 43.1% 0.49�
Median age (range) 57
(35-99)
60
(35-91)
57
(35-99)
<0.0001†
About 90% in all groups listed race as white
JAMA Oncol. 2017 Aug 1;3(8):1112-1115
![Page 12: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/12.jpg)
Screened Unscreened p-valueAll Melanoma cases 50 (24 in situ, 26
invasive)104 (35 in situ, 69 invasive)
Median Breslow thickness of invasive melanomas with known depth ( range)
0.37 mm (0.2mm-1.5mm)
0.65 mm (0.18mm-6.5mm)
0.0006
Breslow thickness distribution• 0.01-0.50 mm 18 20• 0.51-1.00 mm 5 26• 1.01-1.50 mm 3 6• 1.51-2.00 mm 0 5• ≥2.01 mm 0 10
JAMA Oncol. 2017 Aug 1;3(8):1112-1115
![Page 13: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/13.jpg)
Who detected melanoma in screened patients?
All cases Detected by dermatologists
Detected by trained PCP
Detected by PCP who did not train
Number cases 50 14 14 22
In situ melanoma 24 (48%) 8 (57%) 5 (36%) 11 (50%) P=0.51
Median depth of invasive melanoma (range)
0.365mm
(0.2mm-1.5mm)
0.465mm
(0.21mm-1.4mm)
0.35mm
(0.20mm-1.5mm)
0.35mm
(0.21mm-0.65mm)
P=0.49
JAMA Oncol. 2017 Aug 1;3(8):1112-1115
![Page 14: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/14.jpg)
PCP-performed biopsies
# patients with ≥ 1 biopsy to rule out malignancy
433# patients with melanoma 15# patients with NMSC 101# patients with other malignancy 1# patients with benign biopsies 316Biopsy ratio (any malignancy) 1: 3.7Biopsy ratio (melanoma) 1: 28.9
![Page 15: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/15.jpg)
What can I do? Basic Skin Exam“Don’t let perfect be enemy of good”
•Catching the obvious melanomas will save lives at minimum cost• Gown patients, look at skin during
the routine exam• Don’t worry about genitals, inside
the mouth, between the toes• Especially older patients (>50-60
years)
![Page 16: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/16.jpg)
Melanoma can have many different appearances
![Page 17: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/17.jpg)
If you are comfortable, and suspect melanoma, biopsy!
• Ideally, removal is of entire lesion and down to fat
Elliptical excision
Punch excisionSaucerization / Shave biopsy
![Page 18: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/18.jpg)
Dermatologic effects of medications you may prescribe
![Page 19: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/19.jpg)
• HCTZ is a photosensitizing drug• Case-control study• 1,533 case patients with BCC and 8629 case patients with SCC, matched
20:1 for sex and birth year• OR 1.29 for BCC and 3.98 for SCC among high users of HCTZ (>50,000 mg)
• Particularly high risk of SCC among patients < 50 years old• Risk increases with drug exposure
J Am Acad Derm. 2018 Apr;78(4):673-681
![Page 20: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/20.jpg)
Thiazide diuretics and risk of skin cancer: Meta-analysis of observational studies
J Clin Med. Res. 2019; 11(4):247-255.
![Page 21: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/21.jpg)
Thiazide diuretics and skin cancer: Clinical considerations
ØData most concerning for increased risk of SCC; less so for melanoma and BCC
ØCounsel patients on HCTZ about risk of photosensitivity and sun protection
ØConsider alternative antihypertensive drugs for patients with >1 non-melanoma skin cancer, fair skin/ easy burning, high sun exposure
ØLimit cumulative dose of HCTZ if possible
![Page 22: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/22.jpg)
Propranolol may reduce the risk of melanoma recurrence
JAMA Oncol. 2018 Feb 8;4(2):e172908.
![Page 23: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/23.jpg)
Clinical case• Tense pruritic bullae appearing in an 81
year old man 8 months after starting linagliptin
• Resolution with discontinuation of linagliptin
J Diabetes Investig. 2018 Mar;9(2):445-447.
Dipeptidyl-peptidase 4 inhibitor- associate bullous pemphigoid • Rare autoimmune bullous disease • Generalized pruritic tense blisters, mainly in
elderly patients.• Characterized by autoantibodies directed against
hemidesmosomal proteins (BP180 and BP230)
![Page 24: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/24.jpg)
• Retrospective case-control study in
diabetic patients with BP and age/sex/yr
of diagnosis –matched controls
• Association of DPP-4 inhibitor use (not
other diabetic medications) with risk of
BP
• Supported by other studies
• Highest risk with Vildagliptin
• Several cases of resolution with stopping
DPP-4 inhibitor
JAMA Dermatol. 2019;155(2):172-177.
![Page 25: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/25.jpg)
Medical side effects of dermatologic medications you
may encounter
![Page 26: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/26.jpg)
Plaque type psoriasisThere are now 10 biologics
FDA-approved for the treatment of psoriasis!
![Page 27: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/27.jpg)
TNF antagonistsEtanercept• Fusion of 2 human TNF-a receptors
and Fc portion of human IgG1
Adalimumab• Fully human IgG1 monoclonal
antibody to TNF-a
Infliximab• Chimeric (75% human,
25% mouse) antibody to TNF-a
Certolizumab Pegol• PEGylated Fc portion of anti- TNF-a
All FDA-approved to treat psoriasis and psoriatic arthritis
![Page 28: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/28.jpg)
IL-12/23 antagonist p35p19
p40p40
• Ustekinumab: mAb to IL-12/23
IL-23 antagonists
p40
p19 p19
p403 now available:• Guselkumab• Tildrakizumab• Risankizumab
![Page 29: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/29.jpg)
IL-17 antagonistsIL17A IL17A Ixekizumab and Secukinumab
• Fully human mAb to IL-17A• FDA approved for psoriasis
and psoriatic arthritis
BrodalumabFully human mAB to IL-RAFDA approved for psoriasis
![Page 30: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/30.jpg)
Class-specific safety concernsTNF antagonists
• Lupus-like syndrome• Demyelinating disease• Congestive heart failure
exacerbation• Reactivation of Hepatitis B• Small increase in risk of non-
melanoma skin cancer• Salmonella / listeria infection• Melanoma metastasis in
patients with invasive melanoma
IL-17 antagonists• Inflammatory bowel disease• Non-invasive candida / fungal
infection• Suicide (brodalumab)
![Page 31: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/31.jpg)
Inflammatory bowel disease and IL-17 inhibition• In phase 3 clinical trials:• Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15
per 100 patient-years for CD and UC, respectively• Ixekizumab:
• 6480 patient-exposure years• CD: incidence rate = 1.1/1000 patient-exposure years; • UC, incidence rate = 1.9/1000 patient-exposure years).
• Brodalumab: 1 case of CD
J Am Acad Dermatol. 2017 Mar;76(3):441-448. J Dermatolog Treat. 2018 Feb;29(1):13-18.
![Page 32: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/32.jpg)
Candidiasis and tinea infections
• Incidence of mucocutaneous candidiasis is 3-4% for patients on anti-IL-17 antagonists• No evidence of systemic / disseminated candida• Treatable infections
Br J Dermatol. 2017 Jul;177(1):47-62.
![Page 33: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/33.jpg)
Suicide and Brodalumab: 4 cases in psoriasis
J Am Acad Dermatol. 2018 Jan;78(1):81-89. Skin Therapy Lett. 2018 Mar;23(2):1-3.
• Also one in the rheumatoid arthritis trial, and one in a psoriatic arthritis study.
• The FDA analyzed the data available in 2015 and determined no established drug-related risk of suicide or suicidal ideation.
• To date, no additional data correlating brodalumab use and suicide
![Page 34: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/34.jpg)
Screening for tuberculosis
• Recommended prior to starting any biologic• Highest risk of TB reactivation with TNF antagonists• Screening for latent TB- QuantiFERON gold, T spot, or PPD
• PPD not good option if prior BCG vaccination• CXR normal in latent TB
• Patients with latent TB can start biologics once they start on treatment, but need to ensure they complete the course
• TB reactivation is EXTRAPULMONARY in about 2/3 of cases so look beyond the chest x ray
Dixon et al Arthritis Rheum 2006;54:2368-76.
![Page 35: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/35.jpg)
Beyond TB: other infectious concerns with TNF antagonist
• Also consider legionella, histoplasmosis
• Listeria and salmonella are also intracellular bacteria and
TNF antagonists reduce immunity to these food-borne
illnesses
– After warning labels introduced in UK to avoid undercooked
eggs, poultry, and meats, incidence of listeria and salmonella
in users of TNF antagonists decreased by about 73%
Ann Rheum Dis. 2013 Mar;72(3):461-2.
![Page 36: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/36.jpg)
Apremilast• Inhibits PDE4• FDA approved for
psoriasis and psoriatic arthritis•Modest efficacy
• Side Effects• GI primarily- diarrhea• Often reason for
stopping• Depression•Weight loss in about
20%
Biochemical Pharmacology. Volume 83, Issue 12, 15 June 2012, Pages 1583–1590
![Page 37: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/37.jpg)
Easy to miss/ mistreat
![Page 38: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/38.jpg)
Diagnosis: Acute Urticaria
24 y.o. female with rash• Started 3 days ago• No new medications or foods• No joint pain, GI symptoms, fevers• Lesions come and go each dayà resolve
completely, new ones appear
![Page 39: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/39.jpg)
Urticaria
• Presentation: pruritic wheals, single lesions last < 24 hours• Cause• Usually idiopathic• Consider other causes
• Drug• Dermatographism (can induce urticaria by scratching on skin)• Physical urticaria – induced by pressure, vibration, heat or cold• Allergy testing not warranted!• If negative ROS, don’t need lab work
• If lesions last >24 hours, burn more than itch, associated with joint pain, heal with bruising, consider urticarial vasculitis- refer to dermatology
![Page 40: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/40.jpg)
Classifying urticaria
Duration: •Acute (< 6 weeks)•Chronic (>6 weeks)
Allergy. 2018 Jul;73(7):1393-1414
![Page 41: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/41.jpg)
Work up• If angioedema, is patient on ACE-I? If so stop and re-evaluate• Acute Urticaria
• Take a history, but no routine testing unless suspect a particular food as a cause
• Chronic• Good history• Determine if inducible à identify cause• Other associated symptoms?• Routine monitoring (consider):
• CBC with differential• ESR and/ or CRP
“Intensive and costly general screening programs for causes of urticaria are strongly advised against”
Allergy. 2018 Jul;73(7):1393-1414
![Page 42: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/42.jpg)
Hives: induced by
cold
3 min exposure to ice cube
Cold urticaria
![Page 43: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/43.jpg)
Scratch test: Dermatographism
![Page 45: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/45.jpg)
Urticaria
• What about oral steroids?• They will make urticaria go away in most cases while on high-dose
steroids• Urticaria will return with dose tapering/ cessation• Rarely indicated, particularly for chronic urticaria!
![Page 46: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/46.jpg)
Hives, every night
• Hives, onset in the "tingling" symptoms – minimal pruritus
• The rash will fade somewhat throughout the following day to where it almost disappears, only to become red again at the end of the day
• Associated with fevers and joint pain/swelling
• Labs
• CRP 6.1• ESR: 54• Ferritin: 2378
![Page 47: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/47.jpg)
![Page 48: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/48.jpg)
When it may be more than just urticaria
• Adult Onset Still’s Disease• Fever, arthritis, nonpruritic urticaria-like lesions• Classically appear nightly, improve during day• Characterized by markedly elevated ESR, CRP, ferritin• Striking response to NSAIDs
• Consider other causes if• Fever• Unexplained lymphadenopathy• Arthralgias• Lymphadenopathy• Non-pruritic lesions
![Page 49: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/49.jpg)
When wound care continues to fail
•78 year old woman•Healthy• Spontaneously developed open wounds on arms,
trunk•No response to wound care, oral antibiotics• Serial debridement did not improve and actually
worsened disease
![Page 50: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/50.jpg)
![Page 51: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/51.jpg)
Pyoderma gangrenosum
![Page 52: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/52.jpg)
Pyoderma gangrenosum
• Autoinflammatory neutrophilic dermatosis• Non-healing, ulcerated lesions• Exhibit pathergy (worsen with mechanical trauma)• Associated with other neutrophilic or inflammatory disorders • inflammatory bowel disease • rheumatoid arthritis• seronegative arthritis• hematologic disorders, including paraproteninemia, especially Ig A • neutrophilic malignancies such as acute myelogenous leukemia (AML)
![Page 53: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/53.jpg)
DIAGNOSIS OF EXCLUSION!
![Page 54: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/54.jpg)
Topical Therapy• Potent topical steroids• Intralesional steroids• Topical dapsone• Topical tacrolimus
Systemic Therapy• Prednisone (0.5-1 mg/ kg / d)• Cyclosporine (3-5 mg/ kg/d)• Colchicine (0.6-1.2 mg/ d)• Dapsone (50-100 mg / d)• Azathioprine (50-1000 mg BID)• Mycophenolate mofetil (1-1.5 g BID)• Minocycline (100 mg / d)
Biologic Therapy• Anti TNF alpha
§ Infliximab§ Adalimumba
• Anti IL-1§ Anakinra§ Canakinumab§ Gevokizuma
• Anti IL-12/23§ Ustekinumab
Pyoderma gangrenosum therapy
![Page 55: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/55.jpg)
Therapies: cyclosporine, adalimumab, topical clobetasol, topical dapsone, gentle wound care, lots of hand holding over 5 years
![Page 56: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/56.jpg)
![Page 57: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/57.jpg)
Surgical therapy is not the answer!
Initial presentation After surgical re-excision After topical steroids
![Page 58: Top Dermatology Challenges in Primary Care · • In phase 3 clinical trials: • Secukinumab: exposure adjusted incidence rates of 0.11 and 0.15 per 100 patient-years for CD and](https://reader034.vdocument.in/reader034/viewer/2022050313/5f75ee0be79ee815121a8275/html5/thumbnails/58.jpg)
Take-home points• Skin exam during routine physical can improve early detection of
skin cancer
• Consider stopping thiazide diuretics in patients with skin cancer
• Risk of bullous pemphigoid with DPP4 inhibitors
• Patients on biologics:
• Risk of IBD with IL-17 inhibitors
• Risk of TB is low, but consider extrapulmonary TB in patients on TNF
antagonists
• Urticaria: think before you give a steroid taper
• Non-healing wound: consider pyoderma gangrenosum